130 related articles for article (PubMed ID: 32934745)
1. Antitumor effects of ribavirin in combination with TMZ and IFN-β in malignant glioma cells.
Ochiai Y; Sumi K; Sano E; Yoshimura S; Yamamuro S; Ogino A; Ueda T; Suzuki Y; Nakayama T; Hara H; Katayama Y; Yoshino A
Oncol Lett; 2020 Nov; 20(5):178. PubMed ID: 32934745
[TBL] [Abstract][Full Text] [Related]
2. Effect of IFN-beta on human glioma cell lines with temozolomide resistance.
Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E
Int J Oncol; 2009 Jul; 35(1):139-48. PubMed ID: 19513561
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiles predicting the response to IFN-β and a combination of temozolomide and IFN-β in malignant gliomas.
Yoshino A; Tashiro S; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Sano E; Tsumoto K
Int J Oncol; 2011 Sep; 39(3):529-42. PubMed ID: 21805051
[TBL] [Abstract][Full Text] [Related]
4. Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma.
Ono T; Sasajima T; Doi Y; Oka S; Ono M; Kanagawa M; Baden A; Mizoi K; Shimizu H
Nucl Med Biol; 2015 Jul; 42(7):598-607. PubMed ID: 25892210
[TBL] [Abstract][Full Text] [Related]
5. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T
World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of antiglioma effect with combined temozolomide and interferon-beta.
Park JA; Joe YA; Kim TG; Hong YK
Oncol Rep; 2006 Dec; 16(6):1253-60. PubMed ID: 17089046
[TBL] [Abstract][Full Text] [Related]
7. Targeting Aurora kinase B attenuates chemoresistance in glioblastoma via a synergistic manner with temozolomide.
Alafate W; Wang M; Zuo J; Wu W; Sun L; Liu C; Xie W; Wang J
Pathol Res Pract; 2019 Nov; 215(11):152617. PubMed ID: 31563286
[TBL] [Abstract][Full Text] [Related]
8. Synergistic Anticancer Effects of Formononetin and Temozolomide on Glioma C6 Cells.
Zhang X; Ni Q; Wang Y; Fan H; Li Y
Biol Pharm Bull; 2018 Aug; 41(8):1194-1202. PubMed ID: 29848900
[TBL] [Abstract][Full Text] [Related]
9. A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation.
Natsume A; Wakabayashi T; Ishii D; Maruta H; Fujii M; Shimato S; Ito M; Yoshida J
Cancer Chemother Pharmacol; 2008 Apr; 61(4):653-9. PubMed ID: 17564708
[TBL] [Abstract][Full Text] [Related]
10. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
[TBL] [Abstract][Full Text] [Related]
11. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling predicts response to temozolomide in malignant gliomas.
Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E; Tsumoto K
Int J Oncol; 2010 Jun; 36(6):1367-77. PubMed ID: 20428759
[TBL] [Abstract][Full Text] [Related]
13. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
[TBL] [Abstract][Full Text] [Related]
14. Combination Therapy for Gliomas Using Temozolomide and Interferon-Beta Secreting Human Bone Marrow Derived Mesenchymal Stem Cells.
Park JH; Ryu CH; Kim MJ; Jeun SS
J Korean Neurosurg Soc; 2015 May; 57(5):323-8. PubMed ID: 26113958
[TBL] [Abstract][Full Text] [Related]
15. BKM120 sensitizes C6 glioma cells to temozolomide via suppression of the PI3K/Akt/NF-κB/MGMT signaling pathway.
Li M; Liang RF; Wang X; Mao Q; Liu YH
Oncol Lett; 2017 Dec; 14(6):6597-6603. PubMed ID: 29151909
[TBL] [Abstract][Full Text] [Related]
16. Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma.
Rainov NG; Fels C; Droege JW; Schäfer C; Kramm CM; Chou TC
Cancer Gene Ther; 2001 Sep; 8(9):662-8. PubMed ID: 11593335
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of ribavirin against malignant glioma cell lines: Follow-up study.
Ochiai Y; Sano E; Okamoto Y; Yoshimura S; Makita K; Yamamuro S; Ohta T; Ogino A; Tadakuma H; Ueda T; Nakayama T; Hara H; Yoshino A; Katayama Y
Oncol Rep; 2018 Feb; 39(2):537-544. PubMed ID: 29251333
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
Hanihara M; Kawataki T; Oh-Oka K; Mitsuka K; Nakao A; Kinouchi H
J Neurosurg; 2016 Jun; 124(6):1594-601. PubMed ID: 26636389
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of low dose temozolomide in combination with bortezomib in U87 glioma cells: a flow cytometric analysis.
Vlachostergios PJ; Papandreou CN
Arch Med Sci; 2015 Apr; 11(2):307-10. PubMed ID: 25995745
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-195 reverses the resistance to temozolomide through targeting cyclin E1 in glioma cells.
Wang H; Ren S; Xu Y; Miao W; Huang X; Qu Z; Li J; Liu X; Kong P
Anticancer Drugs; 2019 Jan; 30(1):81-88. PubMed ID: 30273182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]